Global Macular Edema Market – Size, Share and Forecasts (2018-2025)

SKU: DPH42 | Published On: 2019-04-09 | Available Formats

Macular Edema Market

  • The global macular edema market was valued at USD 6.24 billion in 2017 and the market is estimated to grow at a CAGR of 10.43% in the forecasted period (2018-2025) to reach a market value of USD XX billion by 2025.

Growth factors of Global Macular Edema Market:

  • Macular Edema is a condition in which fluid gathers in macular and leads to vision impairment and loss of vision in certain conditions.
  • Advancements in technologies in development of new drug delivery systems, introduction of new drug combinations, rise in macular edema patients are the major factors driving the growth of the macular edema market across the globe.
  • Increasing diabetic population which in turn could result in macular edema is also one of the factors driving the growth of the market. Stringent regulations across various regions, availability of alternative therapies, and high cost of the drugs/medication are the major factor restraining the growth of the market.

Global Macular Edema Market Segmentation

  • The macular edema market is segmented by clinical trial analysis, by molecular type, and by geography.
  • By geography, North America has the largest market share in 2017 accounting for more than half of the market value and this is followed by Europe. Emerging markets are witnessing a faster growth in the market with Asia-Pacific region growing at a faster growth rate.

Some of the major companies in global macular edema therapeutics market include

  • Novartis
  • Roche
  • Pfizer
  • Regeneron Pharmaceuticals

Competitive Analysis

  • The global macular edema market is a consolidated market with top 4 companies accounting for the largest market share. Some of the recent industry developments include
  • FDA approves Roche’s “Lucentis” for treatment of diabetic retinopathy in people with diabetic macular edema
  • Eylea injection recommended for approval for the treatment of visual impairment due to diabetic macular edema in the European Union

Reasons to purchase this report

  • Visualize the composition of the macular edema market across each indication, in terms of type and applications, highlighting the key commercial assets and players.
  • Identify commercial opportunities in macular edema by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the macular edema market – level 4/5 segmentation
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
  • Product mapping in excel for the key Macular Edema products of all major market players

Target Audience for this report

  • Raw Material Suppliers/ Buyers
  • Product Suppliers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Global Macular Edema Market

1 Methodology and Scope

1.1 Research methodology

1.2 Scope of the Report

2. Headlines & Trends

2.1 Headlines

2.2 Key Trends & Developments

3. Industry Analysis

3.1 Market Drivers

3.2 Market Restraints

3.3 Porters Five Forces Analysis

3.3.1 Suppliers Power

3.3.2 Buyer Power

3.3.3 Industry Competition

3.3.4 Threat of new Entrant

3.3.5 Threat of Substitutes

4. Clinical Trial Analysis

4.1 By Age Group

4.1.1 Child

4.1.2 Adult

4.1.3 Senior

4.2 By Gender

4.2.1 Male

4.2.2 Female

4.3 By Study Phases

4.3.1 Early Phase

4.3.2 Phase 1

4.3.3 Phase 2

4.3.4 Phase 3

4.3.5 Phase 4

4.4 By Study Type

4.4.1 Interventional

4.4.2 Observational

5. Segmentation by Molecular Type

5.1 Recombinant Protein

5.2 Small Molecule

6. Geographic Analysis

6.1 North America

6.1.1 United States

6.1.2 Canada

6.1.3 Mexico

6.1.4 Others

6.2 Europe

6.2.1 United Kingdom

6.2.2 Spain

6.2.3 Germany

6.2.4 France

6.2.5 Switzerland

6.2.6 Others

6.3 Asia-Pacific

6.3.1 India

6.3.2 China

6.3.3 Australia

6.3.4 Japan

6.3.5 Rest of Asia-Pacific

6.4 South America

6.4.1 Brazil

6.4.2 Argentina

6.4.3 Rest of South America

6.5 Rest of the World

7. Competitive Landscape

7.1 Market Share Analysis

7.2 Company Benchmarking

7.3 Key Strategies Adopted by Major Companies

8. Company Profiles*

8.1 Regeneron Pharmaceuticals

8.2 Novartis

8.3 Pfizer

8.4 Bayer

8.5 Aerie Pharmaceuticals

8.6 Aerpio Therapeutics

8.7 Amipo Pharmaceuticals

8.8 Icon Bioscience

8.9 Roche

8.10 Araim Pharmaceuticals

8.11 Verseon Corp

9. Appendix

9.1 Sources

9.2 List of Charts

9.3 Expert Panel Validation

9.4 Disclaimer

9.5 Contact Us

Buy This Report

To get the free report sample tailored to your requirements

Could not find what you need?

Quick Fact: 7 of 10 customers Tailor their reports

DMI Cognizance Expertise

Massive Repository

10-year historic data for 1000+ markets

Association Networks

Ground-Zero understanding of the market with inputs from relevant industry association members

First Hand Understanding

Tailored interviews with manufacturers, buyers, sellers, distributers and retailers for five-frame understanding of the market

360 Web Research

Analysis of publicly available white label papers, news announcements, press releases, financial reports and reliable paid consulting data

Star Expert Review

7-step data formulation for market analysis and forecasts, under thorough scrutiny of industry-specific consultants with over 20+ years of expertise


Copyright © 2019 DataM Intelligence. All Rights Reserved

Designed and Developed by -Montaigne Labs